ZL 1101

Drug Profile

ZL 1101

Alternative Names: ZL-1101

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator UCB
  • Developer ZAI Lab
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Graft-versus-host disease; Inflammatory bowel diseases

Most Recent Events

  • 04 Aug 2016 Preclinical trials in Inflammatory bowel disease in China (Parenteral)
  • 04 Aug 2016 Preclinical trials in Graft-versus-host disease in China (Parenteral)
  • 22 Sep 2015 Autoimmune diseases therapeutic licensed to Zai Lab worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top